I am trying to track this one after OSL fell from highs. I have hopes for the new CEO but I am not sure how good is the product but management has done this in previous jobs and roles. I will watch the revenue and costs closely. I also think they will have to raise capital in < 12 months from now (maybe 6 months). They have approx 12 mils left and spending 3 mils every qtr.
26 February 2021 Business update call transcript - Notes
Able to assemble an experienced commercial team in Europe and the United States
Approved by the central ethics committee in the UK, which means we can commence with patient treatments
FDA in support of the HDE application. Furthermore, TGA had made an additional request which the team
has completed and forwarded back to TGA last month.
Our immediate focus is on short-term revenue growth and generating cash flow.
I’m confident that we will get first patient dose sales in the
first half of 2021 in Europe, and of course this is going to be in the UK
29 April 2021
Quarterly Activities & Cash Flow Report
Quarter ended 31 March 2021
Additional sales in New Zealand: Following OncoSil’s first ever commercial sale, OncoSil has
achieved further sales in New Zealand
• Cash position: Cash balance of $15.3 million as at 31 March 2021
Europe and UK: 9 hospitals in UK have received ethics approval
In July 2020, the Company filed an application with the Therapeutic Goods Administration (TGA) in
Australia. On 11 January 2021, OncoSil submitted additional data in response to the TGA’s request.
4 May 2021
OncoSil receives regulatory approval from Hong Kong
The approval marks a key step in OncoSil’s commercialisation strategy in Asia, following the approvals
received in Singapore and Malaysia last year
2 June 2021
Australian TGA Update - While Australia is a strategic market in the
future, we remain focused on the European and US markets, where our long-term and material growth
opportunities lie.
20 July 2021
Otto Buttula appointed to the Board of OncoSil
26 July 2021
Quarterly Activities & Cash Flow Report
Quarter ended 30 June 2021
Cash position: Cash balance of $12.2 million as at 30 June 2021.
Europe and UK: Patient screening has been activated at the London Clinic
Germany: The team is targeting 15 leading centers involved in the
treatment of pancreatic cancer.
Spain, the sales team is targeting 6 key hospitals where approval for the Osprey
registry is currently underway. In Italy and Spain, funding for the OncoSil device is expected to occur
through annual allocations of public hospital budgets at a site level, and through the private payer market
in private hospitals.
In Luxembourg, one centre has been identified to adopt the OncoSil device. We anticipate full approval by
the end of October 2021
US: Bile Duct Cancer or Distal Cholangiocarcinoma (DCC) - delays because of covid.
Dr Chris Roberts and Mr Michael Bassett intend to step down from the Board at the time of OncoSil’s Annual General
Meeting, expected to be held in October 2021.
